Revolutionizing the sustained delivery of therapeutics to the eye

SurModics is dedicated to revolutionizing the methods of providing sustained drug delivery to the eye for treatment of debilitating diseases such as age-related macular degeneration (AMD) and diabetic macular edema (DME), which are among the leading causes of blindness in the United States. Over 200,000 people are diagnosed annually with “wet” AMD and in excess of 500,000 diabetics suffer from DME.1,2

SurModics' scientists and engineers are developing systems to broaden the array of technical solutions to treat these diseases and others, which include intravitreal drug delivery, subretinal drug delivery, and other novel drug delivery methods.  With extensive experience in the field of site-specific drug delivery in other areas of medicine, SurModics is now applying this knowledge in the field of ophthalmology to improve the delivery of drugs.

SurModics’ ophthalmic drug delivery options include:

  • Durable and biodegradable drug-eluting coatings for use on devices such as I-vation intravitreal implants
  • Fully biodegradable polymer implants
  • Microparticle injections
  • Delivery of drugs intravitreally or subretinally

Our drug delivery solutions are applicable to a broad range of drugs, from small molecules to proteins.

SurModics' lead product in the field of ophthalmic drug delivery is the I-vation™ intravitreal implant designed to provide controlled and sustained release of a variety of drug compounds to the posterior chamber of the eye for such indications as diabetic macular edema and age-related macular degeneration. 

SurModics seeks to partner with pharmaceutical and medical device companies working in the field of ophthalmology to commercialize our paradigm-changing ophthalmic drug delivery technologies to the benefit of patients and physicians. With a focus on strong, synergistic collaborations, the Company looks to grow the potential of these partnerships by bringing to the table a team of business and technical leaders committed to accelerated innovation and improved patient outcomes.

1Arch. Ophthalmology, 122:564-572, 2004.
2Arch. Ophthalmology, 122:552-563, 2004.